Perfluorohexane
Title: Perfluorohexane
CAS Registry Number: 355-42-0
CAS Name: Tetradecafluorohexane
Additional Names: perfluoro-n-hexane
Trademarks: Imavist (Schering AG)
Molecular Formula: C6F14
Molecular Weight: 338.04
Percent Composition: C 21.32%, F 78.68%
Line Formula: CF3(CF2)4CF3
Literature References: Commercial grade perfluorohexanes contain a mixture of five acyclic C6F14 isomers and two C6F12 perfluorinated cyclic alkanes. Discovery: J. H. Simons, L. P. Block, J. Am. Chem. Soc. 59, 1407 (1937). Prepn and physical properties: V. E. Stiles, G. H. Cady, ibid. 74, 3771 (1952); R. D. Dunlap et al., ibid. 80, 83 (1958). Critical properties and virial coefficients: Z. L. Taylor, Jr., T. M. Reed, III, AIChE J. 16, 738 (1970). Conformational analysis: P. Piaggio et al., J. Mol. Struct. 26, 421 (1975). 19F-NMR characterization of commercial product: T. A. Kestner, J. Fluorine Chem. 36, 77 (1987). Use as a solvent in bromination reactions: S. M. Pereira et al., Synth. Commun. 25, 1023 (1995). Evaluation in acute lung injury in rabbits: M. Hübler et al., Crit. Care Med. 30, 422 (2002).
Properties: Coarse, transparent, needle-like crystals, mp -82.26 ±0.01°. bp 57.23°. d0 1.7560. d25 1.66970 (air satd, 1 atm). d25 1.6717 (degassed, equilib vapor pressure). nD22 1.2515. Viscosity at 0°: 9.79 mP. Heat of fusion: 1580 ±90 cal/mol. Molar heat of vaporization (cal) at bp: 7307; at 20°: 7793.
Melting point: mp -82.26 ±0.01°
Boiling point: bp 57.23°
Index of refraction: nD22 1.2515
Density: d0 1.7560; d25 1.66970 (air satd, 1 atm); d25 1.6717 (degassed, equilib vapor pressure)
Use: In the electronics industry as a coolant and test bath medium. Non-toxic, non-ozone-depleting, inert reaction medium.
Therap-Cat: Diagnostic aid (Ultrasound contrast agent).
Keywords: Diagnostic Aid (Ultrasound Contrast Agent).

Others monographs:
NitrophenideFilipinBenzenearsonic AcidPropargite
IndomethacinEthylene ThioureaCyclizineRidogrel
Thiazol Yellow GAcetylcholine BromideRhamnoseTiagabine
Carbamide PeroxideEthohexadiolAzithromycinIsatin
©2016 DrugLead US FDA&EMEA